Spain· ES:1151043001
NUCALA 100 MG POLVO PARA SOLUCION INYECTABLE
A medicinal product containing mepolizumab, registered in Spain by Glaxosmithkline Trading Services Limited.
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- mepolizumab
- Manufacturer
- Glaxosmithkline Trading Services Limited
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mepolizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNUCALAGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumNucala 100 mgGlaxoSmithKline Trading Services
- United KingdomNucala 100mg powder for solution for injection vialsGlaxoSmithKline UK Ltd
- IcelandNucalaGlaxoSmithKline Trading Services Limited
- PolandNucalaGlaxoSmithKline Trading Services Limited
- SwedenNucala 100 mg Pulver till injektionsvätska, lösningGlaxoSmithKline Trading Services Ltd
- ItalyNUCALA*1 flaconcino SC 100 mgGLAXOSMITHKLINE TRAD.SERV.LTD
- FinlandNucalaGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nucala
- Liechtenstein · Nucala
- Norway · Nucala
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8b878ef6-309d-4b38-a675-68a22fc14dcb GET /v1/drugs/8b878ef6-309d-4b38-a675-68a22fc14dcb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Diagnóstico Hospitalario",
"estado": "{\"aut\":1450306800000}",
"nregistro": "1151043001",
"substance": "mepolizumab"
}See everything about mepolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.